Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease
Sign Up to like & getrecommendations! Published in 2021 at "Hepatology International"
DOI: 10.1007/s12072-021-10200-y
Abstract: Several single-nucleotide polymorphisms have been identified to be disadvantageous or protective in regard to disease severity in patients with non-alcoholic fatty liver disease (NAFLD). However, it is unclear, whether including genetic risk factor(s) either alone… read more here.
Keywords: fibrosis; disease; liver; severity ... See more keywords
Discovery of First-in-Class FXR and HSD17B13 Dual Modulator for the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.4c02720
Abstract: Metabolic dysfunction-associated steatohepatitis (MASH) is a complex disease driven by diverse metabolic and inflammatory pathways. Farnesoid X receptor (FXR) is a promising target for MASH due to its role in bile acid and lipid metabolism,… read more here.
Keywords: modulator; fxr; dysfunction associated; fxr hsd17b13 ... See more keywords
Discovery of the First-In-Class HSD17B13/PPAR Multitarget Modulators for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.5c01825
Abstract: Metabolic dysfunction-associated steatohepatitis (MASH) is a complex disease driven by multiple metabolic and inflammatory pathways. HSD17B13 is a potential therapeutic target for MASH, and PPAR regulates multiple pathological mechanisms related to MASH. Based on their… read more here.
Keywords: ppar; hsd17b13 ppar; mash; hsd17b13 ... See more keywords
Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension
Sign Up to like & getrecommendations! Published in 2020 at "Liver International"
DOI: 10.1111/liv.14304
Abstract: The loss‐of‐function rs72613567 T > TA‐variant in the 17β‐hydroxysteroid dehydrogenase 13 (HSD17B13) gene might protect from alcoholic and non‐alcoholic fatty liver disease (ALD/NAFLD) and associated fibrosis/cirrhosis. We investigated the impact of the T > TA‐variant… read more here.
Keywords: hepatic decompensation; impact; decompensation mortality; rs72613567 ... See more keywords
Fatty liver disease genetic risk variants and interference on sex hormones
Sign Up to like & getrecommendations! Published in 2023 at "Liver International"
DOI: 10.1111/liv.15562
Abstract: Nonalcoholic fatty liver disease (NAFLD), also defined as metabolic dysfunctionassociated fatty liver disease (MAFLD),1 is the leading cause of chronic liver disease worldwide, accounting for up to 30% based on recent global estimates.2 NAFLD comprises… read more here.
Keywords: disease; hsd17b13; sex; risk ... See more keywords
Hydroxysteroid 17β‐dehydrogenase 13 (Hsd17b13) knockdown attenuates liver steatosis in high‐fat diet obese mice
Sign Up to like & getrecommendations! Published in 2025 at "Experimental Physiology"
DOI: 10.1113/ep092535
Abstract: Hydroxysteroid 17β‐dehydrogenase 13 (HSD17B13) loss‐of‐function gene variants are associated with a decreased risk of metabolic dysfunction‐associated steatotic liver disease (MASLD). Our RNA‐seq analysis of steatotic liver from obese mice ± fenretinide treatment identified major beneficial… read more here.
Keywords: hydroxysteroid dehydrogenase; obese mice; expression; liver ... See more keywords
Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients
Sign Up to like & getrecommendations! Published in 2020 at "Gastroenterology Research and Practice"
DOI: 10.1155/2020/4216451
Abstract: A single-nucleotide polymorphism causing a C to G change in the PNPLA3 gene (rs738409) is associated with disease severity and development of hepatocellular carcinoma (HCC) in nonalcoholic fatty liver disease; the insertion variant rs72613567:TA of… read more here.
Keywords: risk; hcc; hepatitis; hsd17b13 ... See more keywords
Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms231911840
Abstract: A common splice variant in HSD17B13 (rs72613567:TA) was recently found to be associated with a reduced risk of developing chronic liver disease in NAFLD patients and a reduced risk of progression to advanced fibrosis and… read more here.
Keywords: decompensation; variant hsd17b13; cirrhotic patients; hsd17b13 ... See more keywords
MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms232415825
Abstract: The severity of hepatic steatosis is modulated by genetic variants, such as patatin-like phospholipase domain containing 3 (PNPLA3) rs738409, transmembrane 6 superfamily member 2 (TM6SF2) rs58542926, and membrane-bound O-acyltransferase domain containing 7 (MBOAT7) rs641738. Recently,… read more here.
Keywords: liver; hsd17b13; mtarc1; hepatic steatosis ... See more keywords